Tesamorelin
Tesamorelin GHRH analog targeting visceral abdominal fat. FDA-approved active ingredient for lipodystrophy.
Start Your VisitClinical Overview
Tesamorelin is a potent GHRH analog with enhanced molecular stability. The active ingredient in FDA-approved Egrifta, it selectively reduces visceral fat while preserving lean muscle mass.
Clinical Safety Framing: Risk, contraindications, interactions, and follow-up planning should be reviewed before initiating any peptide pathway.
Key Benefits
Visceral Fat Targeting — reduces dangerous deep belly fat
Lean Muscle Preservation — maintains muscle during fat loss
Metabolic Improvement — improves insulin sensitivity and lipids
Enhanced Potency — stronger GH stimulation than unmodified GHRH
Frequently Asked Questions
How is it different from sermorelin?
Tesamorelin has a modified structure providing stronger GH stimulation and has published clinical data specifically for visceral fat reduction.
Clinical References & Policies
Global Disclaimer: This content is educational and does not replace individualized medical advice. Treatment decisions should be made with a licensed clinician based on personal history, risk profile, and appropriate monitoring.
Medical Disclaimer: Information provided is for educational purposes only and does not constitute medical advice. All therapies require a consultation with a licensed clinician. Individual results may vary. Compounded medications are prepared by state-licensed 503A pharmacies and are not FDA-approved.
Ready to Get Started?
Same-day telehealth consultation with a licensed clinician.
Start Your Visit